#USA #Castle Biosciences #Friendwood #DecisionDx-SCC #Cutaneous cancer

Castle Biosciences Announces Breakthrough in Cutaneous Cancer Care

Castle Biosciences, Inc., a prominent diagnostics company listed on Nasdaq as CSTL, has made headlines with its recent publication in the Journal of the American Academy of Dermatology (JAAD). This pivotal research validates the enhancements made to the DecisionDx-SCC test, a gene expression profile (GEP) designed for assessing high-risk cutaneous squamous cell carcinoma (SCC).

The DecisionDx-SCC test now integrates clinicopathologic risk factors to produce more precise prognostic outcomes. This improved test not only analyzes 40 genes related to tumor biology but also factors in five key clinicopathologic elements: immunosuppression, tumor diameter, histological differentiation, perineural invasion, and the anatomical site of the tumor. By utilizing optimized nested predictive models, the test offers a comprehensive evaluation of a patient's risk of metastasis, local recurrence, and the potential benefit of adjuvant radiation therapy (ART).

Enhanced Predictive Power

The multi-center study, which included an impressive cohort of 572 patients, revealed groundbreaking results. The DecisionDx-SCC algorithm was successful in significantly stratifying patient risk concerning both metastasis and local recurrence, with statistical significance indicated by p<0.0001 in both factors. This landmark research determined that nearly 45% of the patients were classified as Class 1A (low risk), boasting a remarkable 97.3% negative predictive value (NPV). This level of precision instills confidence for physicians when considering de-escalation of treatment for patients belonging to this category.

On the opposite end of the spectrum, patients classified as Class 2B (highest risk) illustrated a three-year metastasis-free survival rate of 66.2%. This marks a significant difference compared to their Class 1A counterparts, who had a staggering 97.3% survival rate. In multivariable analysis, the Class 2B patients were shown to be 10.7 times more likely to develop metastasis than those in Class 1A, underscoring the efficacy of the DecisionDx-SCC's classification system.

Clinical Implications

The direct clinical applications of these findings are numerous and vital. For instance, patients assigned a Class 2B result are most likely to derive substantial benefits from ART. Those treated with ART exhibited approximately 50% lower progression rates over five years in contrast to their non-ART counterparts. This demonstrates how timely and precise risk assessments can lead to effective treatment plans, ultimately enhancing patient outcomes.

Dr. Désirée Ratner, the lead author and a notable dermatologist, emphasized the challenges in managing high-risk SCC patients. Traditional clinicopathologic staging often lacks the necessary precision, making it difficult to tailor treatment effectively. The refined DecisionDx-SCC test offers clarity by distinguishing which patients require less intensive management and which ones could benefit from further treatment. This aspect alone reduces ambiguity in the care journey for patients and healthcare providers alike.

Continuous Innovation at Castle Biosciences

Rebecca Critchley-Thorne, Ph.D., the Vice President of Research and Development at Castle Biosciences, spoke about the continuous evolution of their testing methods to align with clinical needs. The advancements made to the DecisionDx-SCC reinforce their commitment to delivering clinically actionable information that can support better treatment decisions.

Castle Biosciences plans to continue its dedication toward enhancing diagnostics for dermatological and gastroenterological diseases, ensuring that healthcare professionals have access to rigorous, science-driven solutions that improve patient care.

The study titled, "Validation of the integrated 40-gene expression profile (i40-GEP)," not only adds substantial weight to the evidence supporting the test's efficacy but also draws attention to the need for adaptable, precision-based healthcare solutions in oncology. As Castle Biosciences forges ahead, it sets a new standard for patient management in cutaneous cancer care, ensuring that every individual receives personalized, thoughtful treatment.

For more information about the DecisionDx-SCC and the company’s innovative offerings, visit Castle Biosciences.